Rocket Pharmaceuticals Inc (RCKT) — Cash Flow-to-Debt Ratio
Rocket Pharmaceuticals Inc (RCKT) has a Cash Flow-to-Debt Ratio of -0.96x as of March 2026, meaning its operating cash flow of $-45.39 Million could theoretically repay -1% of its total liabilities ($47.37 Million) in one year. Explore Rocket Pharmaceuticals Inc (RCKT) long-term investment share to see how much of total assets are deployed in long-term investments.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Rocket Pharmaceuticals Inc Cash Flow-to-Debt Ratio (2012–2025)
Historical debt coverage capacity for Rocket Pharmaceuticals Inc across 14 annual periods. Also explore Rocket Pharmaceuticals Inc asset portfolio for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for Rocket Pharmaceuticals Inc (2012–2025)
Year-by-year debt coverage analysis for Rocket Pharmaceuticals Inc. For market capitalisation and broader financial context, see Rocket Pharmaceuticals Inc market cap and net worth.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -3.57x | $-190.01 Million | $53.23 Million | ▼ -9.7% |
| 2024 | -3.25x | $-209.72 Million | $64.47 Million | ▼ -23.1% |
| 2023 | -2.64x | $-194.92 Million | $73.77 Million | ▲ +7.9% |
| 2022 | -2.87x | $-178.14 Million | $62.12 Million | ▼ -0.1% |
| 2021 | -2.86x | $-121.16 Million | $42.30 Million | ▼ -235.1% |
| 2020 | -0.85x | $-74.64 Million | $87.31 Million | ▲ +14.3% |
| 2019 | -1.00x | $-64.66 Million | $64.82 Million | ▼ -6.2% |
| 2018 | -0.94x | $-53.79 Million | $57.28 Million | ▼ -94.3% |
| 2017 | -0.48x | $-26.11 Million | $54.01 Million | ▲ +26.7% |
| 2016 | -0.66x | $-37.27 Million | $56.48 Million | ▲ +82.9% |
| 2015 | -3.86x | $-17.42 Million | $4.51 Million | ▼ -2163.3% |
| 2014 | -0.17x | $-9.74 Million | $57.08 Million | ▼ -36.9% |
| 2013 | -0.12x | $-6.46 Million | $51.76 Million | ▲ +41.8% |
| 2012 | -0.21x | $-6.94 Million | $32.35 Million | — |